TOP TEN perturbations for 1353_g_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1353_g_at
Selected probe(set): 207094_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1353_g_at (207094_at) across 6673 perturbations tested by GENEVESTIGATOR:

systemic lupus erythematosus study 13 (pioglitazone) / pioglitazone study 4 (1uM; 6h)

Relative Expression (log2-ratio):3.590478
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (pioglitazone)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients and cultured with pioglitazone. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. ATC code:
Control pioglitazone study 4 (1uM; 6h)
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and cultured with pioglitazone. Freshly isolated PBMCs were cultured in RPMI/10% FBS in the presence of 1uM pioglitazone for 6 hours. ATC code:

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):3.4017792
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

smoking study 74 (smoker; stim. blood culture) / smoking study 74 (smoker; unstim. blood culture)

Relative Expression (log2-ratio):-2.400217
Number of Samples:20 / 18
Experimental smoking study 74 (smoker; stim. blood culture)
Stimulated peripheral blood cultures from current or former smokers without COPD. One milliliter of peripheral blood was collected into anti-CD3 and anti-CD28 TruCulture tubes and incubated for 24 hours at 37ºC. The TruCulture is an ex-vivo culture system which should preserve physiological cellular responses of immune cells to stress or stimulation at the time and place of sample collection and minimize the bias and variability caused by sample manipulation. Available with/without specific stimulant.
Control smoking study 74 (smoker; unstim. blood culture)
Unstimulated peripheral blood cultures from current or former smokers without COPD. One milliliter of peripheral blood was collected into null TruCulture tubes and incubated for 24 hours at 37ºC. The TruCulture is an ex-vivo culture system which should preserve physiological cellular responses of immune cells to stress or stimulation at the time and place of sample collection and to minimize the bias and variability caused by sample manipulation. Available with/without specific stimulant.

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):-2.281537
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

chronic obstructive pulmonary disease study 21 (smoker; stim. blood culture) / chronic obstructive pulmonary disease study 21 (smoker; unstim. blood culture)

Relative Expression (log2-ratio):-2.2412996
Number of Samples:42 / 46
Experimental chronic obstructive pulmonary disease study 21 (smoker; stim. blood culture)
Stimulated peripheral blood cultures from patients with COPD. Persons included in the study were former or current smokers with smoking status > 10 pack-yr and with FEV1/FVC < 70 post bronchodilator. One milliliter of peripheral blood was collected into anti-CD3 and anti-CD28 TruCulture tubes and incubated for 24 hours at 37ºC. The TruCulture is an ex-vivo culture system which should preserve physiological cellular responses of immune cells to stress or stimulation at the time and place of sample collection and minimize the bias and variability caused by sample manipulation. Available with/without specific stimulant.
Control chronic obstructive pulmonary disease study 21 (smoker; unstim. blood culture)
Unstimulated peripheral blood cultures from patients with COPD. Persons included in the study were former or current smokers with smoking status > 10 pack-yr and with FEV1/FVC < 70 post bronchodilator. One milliliter of peripheral blood was collected into null TruCulture tubes and incubated for 24 hours at 37ºC. The TruCulture is an ex-vivo culture system which should preserve physiological cellular responses of immune cells to stress or stimulation at the time and place of sample collection and minimize the bias and variability caused by sample manipulation. Available with/without specific stimulant.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):-2.0894222
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

asthma study 22 (neutrophilic AIP) / asthma study 22 (paucigranulocytic AIP)

Relative Expression (log2-ratio):1.9859209
Number of Samples:17 / 10
Experimental asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (paucigranulocytic AIP)
Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP).

asthma study 22 (eosinophilic AIP) / asthma study 22 (neutrophilic AIP)

Relative Expression (log2-ratio):-1.8586664
Number of Samples:15 / 17
Experimental asthma study 22 (eosinophilic AIP)
Sputum samples from asthmatic patients with eosinophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).

methylprednisolone; immunoglobulin (IVIG) study 1 / Kawasaki disease study 2 (non-responder)

Relative Expression (log2-ratio):-1.8202171
Number of Samples:4 / 10
Experimental methylprednisolone; immunoglobulin (IVIG) study 1
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after combined treatment with intravenous methylprednisolone (30mg/kg/2h) followed by intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to simple IVIG therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients exhibited good response to the combined therapy. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:, ,
Control Kawasaki disease study 2 (non-responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to be resistant / non-responsive to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.

pediatric septic shock study 3 (infant; subclass B) / normal blood sample (infant)

Relative Expression (log2-ratio):1.8015976
Number of Samples:13 / 17
Experimental pediatric septic shock study 3 (infant; subclass B)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass B. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass B (when all age groups were pooled) was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass B had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.0 - 21.0), maximum number of organ failures 2 (IQR 2 - 3), and an intermediate mortality rate. A significantly greater proportion of patients in subclass B received hydrocortisone for cardiovascular shock.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.